Loading clinical trials...

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

NCT03850782•AbbVie

View on ClinicalTrials.gov

Summary

This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•\- Diagnosis of either open angle glaucoma (OAG) (i.e., primary OAG, pseudoexfoliation glaucoma, pigmentary glaucoma) or ocular hypertension requiring intraocular pressure-lowering treatment.

Exclusion Criteria

•Concurrent or anticipated enrollment in another investigational drug or device study or participation in such a study within 2 months prior to enrolling in this study.
•Previous administration with Bimatoprost SR in the study eye.

Locations (108)

Horizon Eye Specialists & Lasik Centers /ID# 235240

Sun City, Arizona, United States

Atlantis Eye Care /ID# 235530

Huntington Beach, California, United States

Lakeside Vision Center /ID# 234970

Irvine, California, United States

Global Research Foundation /ID# 237350

Los Angeles, California, United States

The Eye Research Foundation /ID# 234521

Newport Beach, California, United States

Byers Eye Institute Stanford /ID# 235544

Palo Alto, California, United States

Foothill Eye Institute /ID# 235640

Pasadena, California, United States

Connecticut Eye Consultants P.C. /ID# 234981

Danbury, Connecticut, United States

Advanced Research, LLC /ID# 236045

Deerfield Beach, Florida, United States

Segal Drug Trials, Inc /ID# 235784

Delray Beach, Florida, United States

Key Dates

Start Date

February 28, 2019

Primary Completion Date

August 8, 2025

Completion Date

August 8, 2025

Last Updated

August 19, 2025

Enrollment

515

ACTUAL participants

Conditions

Open-Angle GlaucomaOcular Hypertension

Interventions

Bimatoprost (SR)

DRUG

DSLT for Reducing Medication in Glaucoma

NCT07390890

Primary Open Angle GlaucomaOcular Hypertension

View study

RECRUITINGNA

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population

NCT05902871

Primary Open Angle GlaucomaOcular Hypertension+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Inclusion Criteria

Exclusion Criteria

DSLT for Reducing Medication in Glaucoma

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

Association Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on Glaucoma

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring